About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Repurposing Inhibitors to Target ARID1A-mutant Ovarian Cancers

by Anjali Aryamvally on March 28, 2018 at 9:53 AM
Font : A-A+

Repurposing Inhibitors to Target ARID1A-mutant Ovarian Cancers

Repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, provides a new therapeutic option for ovarian cancer with mutations in the ARID1A gene. The study conducted by a Wistar research team is published in Cell Reports.

Advertisement


Ovarian cancer is the most lethal gynecological malignancy and the clear cell subtype is particularly notorious for not responding well to conventional chemotherapy , leaving limited treatment options for these patients. The ARID1A gene is mutated in more than 50 percent of cases of ovarian clear cell carcinoma. In normal cells, ARID1A regulates expression of a set of genes by affecting the structure of chromatin - the complex of DNA and proteins in which DNA is packaged in our cells. ARID1A mutations cause loss of the protein or its function, which results in malignant transformation of the cells.

In this study, lead researcher Rugang Zhang, Ph.D., and colleagues showed that ARID1A-mutant ovarian cancers are selectively sensitive to inhibition of another chromatin remodeling enzyme called HDAC2. This finding is consistent with the fact that high HDAC2 expression is known to be associated with poor outcome in this type of cancer.
Advertisement

"HDAC2 and associated enzymes are well established therapeutic targets and a number of HDAC inhibitors have received FDA approval for the treatment of hematopoietic malignancies," said Zhang, deputy director of The Wistar Institute Cancer Center, and professor and co-program leader of the Gene Expression and Regulation Program. "We suggest that these inhibitors might be repurposed to target ARID1A-mutant ovarian cancers."

The Zhang Lab showed that HDAC2 inhibition suppresses proliferation and induces programmed cell death in cells with inactivated ARID1A by promoting expression of the PIK3IP1 gene. PIK3IP1 is a tumor suppressive protein that functions as an inhibitor of an important signaling axis that promotes cells proliferation and survival. Through gene knockdown approaches and genomics experiments, the researchers established that, in the absence of ARID1A, HDAC2 binds to the regulatory elements of the PIK3IP1 gene and represses its expression. As a result, the loss of PIK3IP1 allows the tumor to grow and spread while treatment with HDAC2 inhibitors restores PIK3IP1 expression and blocks tumor progression.

The team explored the use of an FDA-approved HDAC inhibitor and confirmed the therapeutic potential of this treatment in mouse models of ARID1A-inactivated ovarian cancer. According to their observations, this inhibitor slowed tumor growth and abnormal buildup of fluids in the abdomen of the tumor-bearing mice and improved survival.

"We have previously reported on the role of another chromatin remodeling factor, called EZH2, in ARID1A-mutant ovarian cancer with a similar mechanism involving antagonistic regulation of PIK3IP1 expression," said Takeshi Fukumoto, Ph.D., first author of the study and a postdoctoral researcher in the Zhang Lab. "However, it might be advantageous to inhibit EZH2 and HDAC2 simultaneously to keep at bay the development of resistance to either inhibitor alone."

Given that mutations and loss of expression of ARID1A are significantly present in multiple human cancers, the new findings may have broader implications for treatment of a wider array of malignancies.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
Toothache
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Ovarian Cancer Ovarian Pain Premature Ovarian Failure 

Recommended Reading
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of ....
Ovarian Cancer Identification with New Personalized Immunotherapy
Ovarian cancer, which harbors highly reactive killer T cells can be susceptible to personalized ......
Anti-cancer Drug Effective Against Rare Ovarian Cancer
Ponatinib is effective against SCCOHT, a type of ovarian cancer that mostly strikes young women and ...
Genetic Factors Determine How Women With Ovarian Cancer Process Chemotherapy
Genes have an impact on how the body processes chemotherapy drugs and leads to different clinical .....
Ovarian Cancer
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms ...
Ovarian Pain
Ovarian pain is caused due to various conditions like ovarian cysts, ovarian tumors, endometriosis, ...
Premature Ovarian Failure
Premature menopause is ovarian failure which occurs 2 SD in years before a mean menopausal age and p...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use